Hikma PharmaceuticalsHKMPF 82 Buyback Yield % is 0.83 as of Jul. 07, 2026, which is 5% above its 10-year median of 0.79. GuruFocus rates HKMPF with a GF Score™ of 82/100 and a GF Value™ of $28.51 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 291 Drug Manufacturers companies, Hikma Pharmaceuticals ranks better than 81.79% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
Hikma Pharmaceuticals Buyback Yield % Related Terms
Hikma Pharmaceuticals Buyback Yield % Historical Data
* Premium members only.
The historical data trend for Hikma Pharmaceuticals's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKMPF vs ZTS, UTHR, VTRS: Buyback Yield % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Hikma Pharmaceuticals's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hikma Pharmaceuticals Buyback Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Hikma Pharmaceuticals's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Hikma Pharmaceuticals's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hikma Pharmaceuticals (HKMPF) has a Buyback Yield % of 0.83 as of Jul. 07, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Hikma Pharmaceuticals and its competitors. This is near median its historical median of 0.79. According to the industry distribution chart, Hikma Pharmaceuticals ranks #53 out of 291 companies in the Drug Manufacturers industry, placing it in the top 18.2%.
Is Hikma Pharmaceuticals' Buyback Yield % too high?
Hikma Pharmaceuticals' current Buyback Yield % of 0.83 is near median its 10-year median of 0.79. Based on the distribution chart, Hikma Pharmaceuticals ranks #53 out of 291 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Hikma Pharmaceuticals has a GF Score™ of 82/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Hikma Pharmaceuticals' Buyback Yield % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Hikma Pharmaceuticals ranks #53 out of 291 companies for Buyback Yield %. This places Hikma Pharmaceuticals in the top 18% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Drug Manufacturers company?
A good Buyback Yield % depends on the Drug Manufacturers industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Hikma Pharmaceuticals and its competitors. Hikma Pharmaceuticals's current Buyback Yield % is 0.83, which is near median its own 10-year median of 0.79. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hikma Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Hikma Pharmaceuticals (HKMPF) is currently considered Modestly Undervalued. The stock's GF Value™ is $28.51, compared to a current price of $20.12 — trading 29.4% below its estimated fair value. The current Buyback Yield % is 0.83, which is near median its 10-year median of 0.79. Hikma Pharmaceuticals' overall GF Score™ is 82/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Hikma Pharmaceuticals (HKMPF), the current Buyback Yield % is 0.83 as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hikma Pharmaceuticals (HKMPF) Overvalued in 2026?
Based on GuruFocus' analysis, Hikma Pharmaceuticals stock appears to be undervalued.
The current stock price of $20.12 is trading 29.4% below its estimated GF Value™ of $28.51.
GuruFocus considers Hikma Pharmaceuticals to be Modestly Undervalued.
Key valuation signals for HKMPF:
Buyback Yield %: 0.83 (near median its 10-year median of 0.79)
GF Value™: $28.51 vs. price of $20.12 (29.4% below fair value)
No single metric tells the full story. See the HKMPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hikma Pharmaceuticals PLC is engaged in developing, manufacturing, and marketing a broad range of generic, branded, and in-licensed pharmaceutical products. The firm operates in three segments: injectables, Rx, and branded. The majority of the company's revenue is generated from its injectables segment, which supplies hospitals across markets with generic injectable products, supported by its manufacturing facilities. Geographically, North America is the company's key revenue-generating market, followed by the Middle East and North Africa, the United Kingdom, Europe, and the rest of the world.
82GF Score
Get the complete analysis for HKMPF
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKMPF has been successfully added to your 
